Rising Diabetes Prevalence in the Middle East and North Africa

By Melike Belenli Gümüş

November 20, 2024

A recent article from the World Health Organization (WHO) provides a comprehensive overview of the global diabetes epidemic, showcasing alarming trends, particularly in the Middle East and North Africa. The focus on the “rising diabetes rates” within these regions highlights the urgent need for intervention and policy changes to combat this health crisis.

Global Epidemiology and Estimates

The number of adults living with diabetes worldwide has surpassed 800 million, more than quadrupling since 1990. Global diabetes prevalence in adults rose from 7% to 14% between 1990 and 2022. By 2022, almost 450 million adults aged 30 and older – about 59% of all adults with diabetes – remained untreated, with a staggering 90% of these untreated individuals residing in low- and middle-income countries (LMICs).

Regional Focus: Middle East and North Africa

The article highlights regional trends related to rising diabetes rates in the Middle East and North Africa:

– The prevalence of diabetes among adults aged 18 and older is particularly concerning in certain areas. Although the exact statistics for the Middle East and North Africa are not specified, the article mentions that the WHO South-East Asia and Eastern Mediterranean Regions have some of the highest diabetes prevalence rates among adults aged 18 and older, around 20%.
– The Middle East and North Africa are projected to see an alarming 87% increase in the number of people with diabetes by 2045.

Burden of Diabetes

The treatment gap is a significant challenge in these regions. The article notes that the Eastern Mediterranean Region, which includes parts of the Middle East and North Africa, has one of the lowest rates of diabetes treatment coverage, with fewer than 4 in 10 adults with diabetes taking glucose-lowering medication.

The economic and health burden is substantial. Global health expenditure on diabetes was estimated at $966 billion in 2021 and is expected to reach $1 trillion by 2045, with a significant portion of this burden falling on LMICs, including those in the Middle East and North Africa.

Urgent Action Needed

The WHO emphasises the need for urgent action to combat rising diabetes rates and the widening treatment gaps, particularly in LMICs. This includes enacting policies that support healthy diets, physical activity, and improving health systems for prevention, early detection, and treatment.

In summary, the Middle East and North Africa regions are experiencing a significant rise in diabetes cases, with high prevalence rates and substantial treatment gaps. Addressing these issues through policy changes, improved health systems, and increased access to treatment is crucial to mitigate the growing burden of diabetes. Urging action on rising diabetes rates is necessary to improve health outcomes in these vulnerable areas.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.